Virax Biolabs Group Limited Ordinary Shares
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.3156
- Today's High:
- $0.36
- Open Price:
- $0.345
- 52W Low:
- $0.3156
- 52W High:
- $3.74
- Prev. Close:
- $0.371
- Volume:
- 311596
Company Statistics
- Market Cap.:
- $6.42 million
- Book Value:
- 0.587
- Revenue TTM:
- $8561
- Operating Margin TTM:
- -66963.69%
- Gross Profit TTM:
- $-1365
- Profit Margin:
- 0%
- Return on Assets TTM:
- -72.67%
- Return on Equity TTM:
- -141.63%
Company Profile
Virax Biolabs Group Limited Ordinary Shares had its IPO on 2022-07-21 under the ticker symbol VRAX.
The company operates in the Healthcare sector and Biotechnology industry. Virax Biolabs Group Limited Ordinary Shares has a staff strength of 11 employees.
Stock update
Shares of Virax Biolabs Group Limited Ordinary Shares opened at $0.35 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.32 - $0.36, and closed at $0.36.
This is a -2.97% slip from the previous day's closing price.
A total volume of 311,596 shares were traded at the close of the day’s session.
In the last one week, shares of Virax Biolabs Group Limited Ordinary Shares have increased by 0%.
Virax Biolabs Group Limited Ordinary Shares's Key Ratios
Virax Biolabs Group Limited Ordinary Shares has a market cap of $6.42 million, indicating a price to book ratio of 0 and a price to sales ratio of 712.5641.
In the last 12-months Virax Biolabs Group Limited Ordinary Shares’s revenue was $8561 with a gross profit of $-1365 and an EBITDA of $0. The EBITDA ratio measures Virax Biolabs Group Limited Ordinary Shares's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Virax Biolabs Group Limited Ordinary Shares’s operating margin was -66963.69% while its return on assets stood at -72.67% with a return of equity of -141.63%.
In Q1, Virax Biolabs Group Limited Ordinary Shares’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Virax Biolabs Group Limited Ordinary Shares’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.49 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Virax Biolabs Group Limited Ordinary Shares’s profitability.
Virax Biolabs Group Limited Ordinary Shares stock is trading at a EV to sales ratio of 1133.8641 and a EV to EBITDA ratio of -7.5208. Its price to sales ratio in the trailing 12-months stood at 712.5641.
Virax Biolabs Group Limited Ordinary Shares stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $9.81 million
- Total Liabilities
- $908401.00
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Virax Biolabs Group Limited Ordinary Shares ended 2024 with $9.81 million in total assets and $0 in total liabilities. Its intangible assets were valued at $9.81 million while shareholder equity stood at $9.13 million.
Virax Biolabs Group Limited Ordinary Shares ended 2024 with $0 in deferred long-term liabilities, $908401.00 in other current liabilities, 1557.00 in common stock, $-11794460.00 in retained earnings and $0 in goodwill. Its cash balance stood at $9.35 million and cash and short-term investments were $9.35 million. The company’s total short-term debt was $146,250 while long-term debt stood at $0.
Virax Biolabs Group Limited Ordinary Shares’s total current assets stands at $9.63 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $232.00 compared to accounts payable of $159908.00 and inventory worth $5237.75.
In 2024, Virax Biolabs Group Limited Ordinary Shares's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Virax Biolabs Group Limited Ordinary Shares paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.36
- 52-Week High
- $3.74
- 52-Week Low
- $0.3156
- Analyst Target Price
- $
Virax Biolabs Group Limited Ordinary Shares stock is currently trading at $0.36 per share. It touched a 52-week high of $3.74 and a 52-week low of $3.74. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0.38 and 200-day moving average was $0.6 The short ratio stood at 0.05 indicating a short percent outstanding of 0%.
Around 3537.6% of the company’s stock are held by insiders while 921.5% are held by institutions.
Frequently Asked Questions About Virax Biolabs Group Limited Ordinary Shares
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual’s immunological profiling data and provide advice on the users’ immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.